It is apparent that mathematical models of tumor–immune interaction with respect to HER2-targeted therapy and/or immune checkpoint blockade can be used to explore tumor dynamics in detail and to answer questions that are difficult to answer by clinical analysis [54,71,145]. Here, ERBB2 is linked to neoplasm.